Doxazosin, an α-1-adrenergic-receptor Antagonist, for Nightmares in Patients with Posttraumatic Stress Disorder and/or Borderline Personality Disorder: a Chart Review

Abstract

Objective: Centrally active α-1-adrenergic-receptor antagonists such as prazosin are effective in the treatment of nightmares in patients with posttraumatic stress disorder (PTSD). A pharmacological alternative is doxazosin, which has a longer half-life and fewer side effects. However, doxazosin is currently being used without solid empirical evidence. Furthermore, no study so far has assessed the effects of α-1-antagonists on nightmares in patients with borderline personality disorder (BPD). We retrospectively assessed the effectiveness of doxazosin on nightmares in PTSD and BPD.

Method: A retrospective chart review of patients treated with doxazosin for trauma-associated nightmares in our clinic was performed. As in previous prazosin studies, the B2 score of the Clinician-Administered PTSD Scale (CAPS) was used as the primary outcome measure. Furthermore, the Pittsburgh Sleep Quality Index-Addendum for PTSD (PSQI-A) and sleep logs were analyzed.

Results: We identified 51 patients with PTSD and/or BPD (mean age 35.7 years, 92.3% women) who received doxazosin for nightmares. Of these, 46 patients continued doxazosin over a 4-week period and 31 patients over a 12-week period. Within the 12-week period, doxazosin treatment significantly reduced nightmares regardless of PTSD/BPD. 25 percent of patients treated for 12 weeks had full remission of nightmares. PSQI-A scores indicated that additional trauma-associated sleep symptoms improved over 12 weeks. Furthermore, recuperation of sleep improved with doxazosin within the first 4 weeks of treatment.

Conclusion: Doxazosin might improve trauma associated nightmares and more general sleep parameters in patients with PTSD and BPD. Randomized controlled trials are warranted.

Key words

doxazosin - posttraumatic stress disorder - PTSD - borderline personality disorder - BPD - nightmares - sleep - retrospective chart review

• References

• 1 Spoormaker VI, Montgomery P. Disturbed sleep in post-traumatic stress disorder: secondary symptom or core feature?. Sleep medicine reviews 2008; 12: 169-184
• 2 Krakow B, Haynes PL, Warner TD et al. Nightmares, insomnia, and sleep-disordered breathing in fire evacuees seeking treatment for posttraumatic sleep disturbance. Journal of traumatic stress 2004; 17: 257-268
• 3 Escamilla M, LaVoy M, Moore BA et al. Management of post-traumatic nightmares: a review of pharmacologic and nonpharmacologic treatments since 2010. Current psychiatry reports 2012; 14: 529-535
• 4 Pietrek C, Elbert T, Weierstall R et al. Childhood adversities in relation to psychiatric disorders. Psychiatry research 2013; 206: 103-110
• 5 Semiz UB, Basoglu C, Ebrinc S et al. Nightmare disorder, dream anxiety, and subjective sleep quality in patients with borderline personality disorder. Psychiatry and clinical neurosciences 2008; 62: 48-55
• 6 Schredl M, Paul F, Reinhard I et al. Sleep and dreaming in patients with borderline personality disorder: a polysomnographic study. Psychiatry research 2012; 200: 430-436
• 7 Germain A, Buysse DJ, Nofzinger E. Sleep-specific mechanisms underlying posttraumatic stress disorder: integrative review and neurobiological hypotheses. Sleep medicine reviews 2008; 12: 185-195
• 8 Raskind MA, Peskind ER, Kanter ED et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. The American journal of psychiatry 2003; 160: 371-373
• 9 Raskind MA, Peskind ER, Hoff DJ et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biological psychiatry 2007; 61: 928-934
• 10 Taylor FB, Martin P, Thompson C et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biological psychiatry 2008; 63: 629-632
• 11 Aurora RN, Zak RS, Auerbach SH et al. Best practice guide for the treatment of nightmare disorder in adults. Journal of clinical sleep medicine 2010; 6: 389-401
• 12 Ziegenhorn AA, Roepke S, Schommer NC et al. Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial. Journal of clinical psychopharmacology 2009; 29: 170-173
• 13 Humphreys JE, Waite MA. Alpha-1 blockers: a new generation of antihypertensive agents. Journal of clinical pharmacy and therapeutics 1989; 14: 263-283
• 14 De Jong J, Wauben P, Huijbrechts I et al. Doxazosin treatment for posttraumatic stress disorder. Journal of clinical psychopharmacology 2010; 30: 84-85
• 15 First MB, Spitzer RL, Gibbon M et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, D.C: American Psychiatric Press, Inc.; 1996
• 16 Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of clinical psychiatry 1998; 59 (Suppl. 20) 22-33 quiz 34–57
• 17 First MB, Gibbon M, Spitzer RL et al. Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II). Washington, D.C: American Psychiatric Press, Inc; 1997
• 18 Blake DD, Weathers FW, Nagy LM et al. The development of a clinician-administered PTSD scale. Journal of traumatic stress 1995; 8: 75-90
• 19 Germain A, Hall M, Krakow B et al. A brief sleep scale for posttraumatic stress disorder: Pittsburgh Sleep Quality Index Addendum for PTSD. Journal of anxiety disorders 2005; 19: 233-244
• 20 Liendl S, Hoffmann R.. Sleep logs: about problems with compliance – development of a short version of standard questionnaires. Somnologie 1999; 3: 73-77
• 21 Kung S, Espinel Z, Lapid MI. Treatment of nightmares with prazosin: a systematic review. Mayo Clinic proceedings 2012; 87: 890-900
• 22 Augedal AW, Hansen KS, Kronhaug CR et al. Randomized controlled trials of psychological and pharmacological treatments for nightmares: a meta-analysis. Sleep medicine reviews 2013; 17: 143-152
• 23 Kobayashi I, Boarts JM, Delahanty DL. Polysomnographically measured sleep abnormalities in PTSD: a meta-analytic review. Psychophysiology 2007; 44: 660-669
• 24 Mellman TA, Kobayashi I, Lavela J et al. A relationship between REM sleep measures and the duration of posttraumatic stress disorder in a young adult urban minority population. Sleep 2014; 37: 1321-1326
• 25 Laitman BM, Gajewski ND, Mann GL et al. The alpha1 adrenoceptor antagonist prazosin enhances sleep continuity in fear-conditioned Wistar-Kyoto rats. Progress in neuro-psychopharmacology & biological psychiatry 2014; 49: 7-15
• 26 Germain A, Richardson R, Moul DE et al. Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US military veterans. Journal of psychosomatic research 2012; 72: 89-96
• 27 Taylor FB, Lowe K, Thompson C et al. Daytime prazosin reduces psychological distress to trauma specific cues in civilian trauma posttraumatic stress disorder. Biological psychiatry 2006; 59: 577-581
• 28 Banzhaf A, Ritter K, Merkl A et al. Gender differences in a clinical sample of patients with borderline personality disorder. Journal of personality disorders 2012;